<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9367">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984995</url>
  </required_header>
  <id_info>
    <org_study_id>AC220-A-J201</org_study_id>
    <secondary_id>JAPIC CTI-163441</secondary_id>
    <nct_id>NCT02984995</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation</brief_title>
  <official_title>Phase 2 Open-label, Single-arm Study of Quizartinib (AC220) Monotherapy in Japanese Patients With FLT3-ITD Positive Refractory or Relapsed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multi-center, open-label, single-arm study to evaluate the efficacy,
      safety and pharmacokinetics of quizartinib monotherapy in Japanese subjects with FLT3-ITD
      positive refractory or relapsed acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite complete remission (CRc) rate</measure>
    <time_frame>Cycle 2 and on: Day 1, within about 12 months</time_frame>
    <description>The composite complete remission (CRc) rate in quizartinib monotherapy in Japanese patients with FLT3-ITD positive refractory or relapsed acute myeloid leukemia (AML) is based on bone marrow findings, absolute neutrophil count and platelet count.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving best response</measure>
    <time_frame>Cycle 2 and on: Day 1, within about 12 months</time_frame>
    <description>There are several categories for best response. The number of participants achieving each of them will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving best response</measure>
    <time_frame>Cycle 2 and on: Day 1, within about 12 months</time_frame>
    <description>Percentage of participants achieving each categorical best response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with overall survival (OS)</measure>
    <time_frame>Event driven, within about 12 months</time_frame>
    <description>OS from registration (enrollment) until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with event free survival (EFS)</measure>
    <time_frame>Event driven - within about 12months</time_frame>
    <description>EFS from registration until documented disease progression/treatment failure, relapse or death from any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with leukemia-free survival (LFS)</measure>
    <time_frame>Event driven - within about 12 months</time_frame>
    <description>LFS from the first documented response of &lt;spell out acronym please&gt; (CRc) until documented relapse or death from any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing adverse events</measure>
    <time_frame>From signing of informed consent form through 30 days after last dose, within about 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the area under the plasma concentration time curve (AUC) of quizartinib and its active metabolite</measure>
    <time_frame>From Cycle 1 to Cycle 3, within about 12 months</time_frame>
    <description>AUC measured at Cycle 1, Days 1, 2, 8, 15, 16; Cycle 2, Day 1; Cycle 3, Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the maximum plasma concentration (Cmax) of quizartinib and its active metabolite</measure>
    <time_frame>From Cycle 1 to Cycle 3, within about 12 months</time_frame>
    <description>Cmax measured at Cycle 1, Days 1, 2, 8, 15, 16; Cycle 2, Day 1; Cycle 3, Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the trough plasma concentration (Ctrough) of quizartinib and its active metabolite</measure>
    <time_frame>From Cycle 1 to Cycle 3, within about 12 months</time_frame>
    <description>Ctrough measured at Cycle 1, Days 1, 2, 8, 15, 16; Cycle 2, Day 1; Cycle 3, Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the time to reach maximum plasma concentration (Tmax) of quizartinib and its active metabolite</measure>
    <time_frame>From Cycle 1 to Cycle 3, within about 12 months</time_frame>
    <description>Tmax measured at Cycle 1, Days 1, 2, 8, 15, 16; Cycle 2, Day 1; Cycle 3, Day 1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Quizartinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-daily repeated oral administration until there is no longer clinical benefit from therapy, or until unacceptable toxicity occurs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quizartinib</intervention_name>
    <description>A novel second-generation FLT3 inhibitor</description>
    <arm_group_label>Quizartinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML patients in first relapse or refractory after all prior therapy

          -  Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2

        Exclusion Criteria:

          -  Diagnosis of acute promyelocytic leukemia

          -  AML secondary to prior chemotherapy for other neoplasms.

          -  Persistent, clinically significant &gt; Grade 1 non-hematologic toxicity from prior AML
             therapy

          -  Prior treatment with a FLT3 targeted therapy

          -  Active infection not well controlled by antibacterial, antifungal and/or antiviral
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Taiga Takagi</last_name>
    <phone>+81-3-5740-3748</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 13, 2016</lastchanged_date>
  <firstreceived_date>December 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FLT3-ITD</keyword>
  <keyword>Positive refractory or relapsed acute myeloid leukemia</keyword>
  <keyword>Hematology malignancy</keyword>
  <keyword>Developmental Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
